Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Carsten Weishaupt, Patrick Terheyden, Beate Schmitt-Bormann, Erika Richtig et al.
Citations
5 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
5.23
article
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Carsten Weishaupt, Patrick Terheyden, Beate Schmitt-Bormann, Erika Richtig, Peter Brossart, Casilda Llácer Pérez, Ioannis Thomas, Célèste Lebbé, Sebastian Ochsenreither, Lucie Heinzerling, Sven D. Koch, Marina Sekacheva, Jürgen Krauß, Paula Codó, Ulrike Gnad-Vogt, Thomas Eigentler, Yulia Semiletova, Juan Martín-Liberal, Gianluca Quintini, Игорь Вячеславович Самойленко, A. Oberoi, Marina González, Michael Fluck, Peter Wengenmayer, Martin Falk, Ainara Soria, Tobias Seibel, Oliver Schönborn‐Kellenberger, Lukas Koch, Artem Poltoratskiy, Caroline Robert, Jana Heß, Michael Erdmann, Peter Mohr, Franz Bauernfeind
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 13(2)
Institutions
Institut Català d'Ornitologia (ES), Inserm (FR), St Petersburg University (RU), Medical University of Graz (AT), Université Paris Cité (FR), Université Paris-Saclay (FR), University Hospital Bonn (DE), Institut Gustave Roussy (FR), LMU Klinikum (DE), Humboldt-Universität zu Berlin (DE), Universitätsklinikum Erlangen (DE), Russian Cancer Research Center NN Blokhin (RU), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), University Hospital Münster (DE), Institut Català d'Oncologia (ES), National Center for Tumor Diseases (DE), Institute of Oncology NN Petrov (RU), Ministry of Health of the Russian Federation (RU), CureVac (Germany) (DE), Vall d'Hebron Hospital Universitari (ES), Elbe Kliniken Stade-Buxtehude (DE), Hôpital Saint-Louis (FR), Comprehensive Cancer Center Erlangen (DE), Fachklinik Hornheide (DE), Hospital Universitario Ramón y Cajal (ES), Instituto de Investigación Biomédica de Málaga (ES), Vall d'Hebron Institute of Oncology (ES), Bayer (Germany) (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE), University of Lübeck (DE)
Funders
Amgen, Bristol-Myers Squibb, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Incyte